secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2024-11-27T23:59:59+00:00
Accession:  0001104659-24-123554
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics' ONS-5010 misses key endpoint in NORSE EIGHT trial; BLA resubmission planned Q1 2025
--------------------------------------------------------------------------------

- ONS-5010 did not meet non-inferiority endpoint at week 8 vs ranibizumab (difference -2.257 BCVA letters, margin -3.5).
- Mean BCVA improvement: ONS-5010 +4.2 letters, ranibizumab +6.3 letters (p=0.0863).
- Favorable safety profile: no retinal vasculitis, ocular AE rates comparable to ranibizumab.
- Final month 3 data expected Jan 2025; BLA resubmission to FDA in calendar Q1 2025.
- EU/UK marketing authorization already granted; launch in UK and Germany planned for 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924123554/0001104659-24-123554-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924123554/tm2429443d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-123554

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer